Vasoactive substance resistance mechanisms in diagnosis and treatment of end-stage liver diseases: Disputes and counter-measurement
10.3969/j.issn.1001-5256.2022.10.040
- VernacularTitle:终末期肝病血管活性物抵抗发生机制与诊疗关系的争议和对策
- Author:
Jianjun LIU
1
;
Wenkai ZHENG
1
;
Jianghong WANG
1
;
Yanjun REN
1
;
Yan LIU
1
;
Lizhen ZHAO
1
Author Information
1. Department of Gastroenterology, The Second Hospital of Handan City, Handan, Hebei 056001, China
- Publication Type:Reviews
- Keywords:
End-Stage Liver Disease;
Vasoconstrictor Agents;
Vasodilator Agents
- From:
Journal of Clinical Hepatology
2022;38(10):2408-2411
- CountryChina
- Language:Chinese
-
Abstract:
The vasoactive substance resistance (VSR) in the end-stage liver disease (ESLD) refers as the reduction of patients' responsiveness to endogenous and exogenous vasoactive substances, cardiac and vascular excitability, peripheral circulatory dysfunction, but induction of related adverse events. VSR is closely related to pathogenesis and treatment-related ESLD complications. However, to date, there are so many unsolved issues, like 1). The cause and underlying mechanism of VSR in ESLD patients; 2). VSR and ESLD multiple organ damages; 3). The preventive and mitigated measurement of VSR; and 4). VSR vasoactive drug use in ESLD patients. This review discussed and summarized the up to date progress in this field of research and clinical VSR in patients with ESLD, i.e., VRS in ESLD patients, disputes of vasoconstrictor drug therapy in ESLD patients, and future research direction of the field.
